The NCRI Skin Group brings together clinicians, scientists and patients, carers and others affected by cancer (also known as ‘consumers’), amongst many others, to coordinate the development of a strategic portfolio of research within the field of skin cancer. The group works closely with clinical research networks, funders and researchers to develop research to improve outcomes for skin cancer patients.  

The NCRI Skin Group consists of an executive group that provides oversight of the research landscape and proactively identifies opportunities for the group. The NCRI Skin Group also has several subgroups that develop research in areas of strategic need.

How can I get involved?

Join the NCRI Skin Network

Professor Rowan Pritchard Jones

Chair

Rowan trained in Bristol as a Plastic Reconstructive Surgeon with a special interest in skin canc ...

Professor Rowan Pritchard Jones

Chair

Rowan trained in Bristol as a Plastic Reconstructive Surgeon with a special interest in skin cancer. Rowan has worked all over the world, earning his cancer Fellowship in the United States and working with the US Army Trauma Team. He has performed cleft reconstruction in the Nepalese Himalayas and served as a British Military Surgeon. Rowan specialises in skin cancer reconstruction as both surgeon and academic holding a chair at Edge Hill University and associate chair at Liverpool University where his team specialises in chemoresistance in melanoma. He leads research nationally for the British Association of Plastic Reconstructive Surgeons, and regionally for NIHR. He also leads and runs a number of clinical trials offering patients the opportunity to be part of world-class research.

Dr Brent O'Carrigan

Deputy Chair

Dr O’Carrigan is a consultant medical oncologist specialising in melanoma at Addenbrooke’s Ho ...

Dr Brent O'Carrigan

Deputy Chair

Dr O’Carrigan is a consultant medical oncologist specialising in melanoma at Addenbrooke’s Hospital, Cambridge. He trained in Sydney and London, completing a fellowship in early phase oncology trials at the Royal Marsden Hospital and PhD in translational cancer research in immuno-oncology at the University of Cambridge. He is PI for a broad portfolio of melanoma academic and commercial clinical trials including cellular therapy trials. He is also the Cancer Lead for the NHS Genomics Laboratory Hub (GLH), East of England.